Overview

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel